Clinical Trial Update: Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study of MDX-010 in patients with unresectable stage III or stage IV malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• MDX-010 (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED